Items Tagged ‘targeted therapy’

November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


June 7th, 2016

First Targeted Therapy Shows Promise in Small Cell Lung Cancer

By

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be substantial, long-term survival for patients with SCLC remains poor. Survival in SCLC is no more than 15%, 2 […]

View full entry

Tags: antibody-drug conjugate, DLL3, Lung Cancer, Lung Cancer - Non-Small Cell, News, Recurrent Lung Cancer - Non-Small Cell, Rova-T, Rovalpituzumab tesirine, sclc, small cell lung cancer, targeted therapy


May 30th, 2016

New Breakthrough May Advance Triple Negative Breast Cancer Treatment

By

By Helen Young Scientists at The Scripps Research Institute have developed a new drug candidate that lowers the growth rate of tumor cells in animal models1 in one of the most difficult cancers to battle: triple negative breast cancer. This is the first time that scientists have been able to take a genetic sequence and design […]

View full entry

Tags: Breast Cancer, genetic sequence, microRNA, microRNA-96, News, RNA, Targaprimir-96, targeted therapy, Triple Negative Breast Cancer


May 19th, 2015

Target Therapy Sutent® Promising in Advanced Thyroid Cancer

By

The targeted therapy Sutent® (sunitinib) appears effective in the treatment of patients with advanced differentiated thyroid cancers. The Endocrine Society announced these Phase II trial findings in a press release. Study results were also presented at the Endocrine Society’s 97th annual meeting in San Diego, March 5–8, 2015. Differentiated thyroid cancer is the most common […]

View full entry

Tags: News, sunitinib, Sutent, targeted therapy, Thyroid Cancer